Plasma HIV RNA decline and emergence of drug resistance mutations among patients with multiple virologic failures receiving resistance testing-guided HAART

AIDS Research and Human Retroviruses

Volumn 24, Issue 6, 2008, Pages 787-796

  Tozzi, Valerio ^a   Bellagamba, Rita ^a   Castiglione, Filippo ^b   Amendola, Alessanda ^a   Ivanovic, Jelena ^a   Nicastri, Emanuele ^a   Libertone, Raffaella ^a   D'Offizi, Giampiero ^a   Liuzzi, Giuseppina ^a   Gori, Caterina ^a   Forbici, Federica ^a   D'Arrigo, Roberta ^a   Bertoli, Ada ^a   Salvatori, Maria Flora ^a   Capobianchi, Maria Rosaria ^a   Antinori, Andrea ^a   Perno, Carlo Federico ^a   Narciso, Pasquale ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; AMPRENAVIR PLUS RITONAVIR; ANTIRETROVIRUS AGENT; DARUNAVIR; ENFUVIRTIDE; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; MALE; PATIENT COMPLIANCE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHI-SQUARE DISTRIBUTION; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; GENOTYPE; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; ITALY; MALE; MIDDLE AGED; MUTATION; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PROSPECTIVE STUDIES; RNA, VIRAL; TIME FACTORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 45749102915     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0236     Document Type: Article

References (31)

1. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122.
2. Perelson AS, Neumann AU, Markowitz M, Leonard JM, and Ho DD: HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-1586.
3. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
4. Louie M, Hogan C, Di Mascio M, et al.: Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis 2003;187:896-900.
5. Wu H, Lathey J, Ruan P, et al.: Relationship of plasma HIV-1 RNA dynamics to baseline factors and virological responses to highly active antiretroviral therapy in adolescents (aged 12-22 years) infected through high-risk behavior. J Infect Dis 2004;189:593-601.
6. Wu H, Mellors J, Ruan P, McMahon D, Kelleher D, and Lederman MM: Viral dynamics and their relations to baseline factors and longer term virologic responses in treatment-naive HIV-1-infected patients receiving abacavir in combination with HIV-1 protease inhibitors. J Acquir Immune Defic Syndr 2003;33:557-563.
7. Boyd MA, Dixit NM, Siangphoe U, et al.: Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: A randomized, controlled trial (HIV-NAT 012). J Infect Dis 2006;194:1319-1322.
8. Kuritzkes DR, Ribaudo HJ, Squires KE, et al.: Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. J Infect Dis 2007;195:1169-1176.
9. Polis MA, Sidorov IA, Yoder C, et al.: Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet 2001;358:1760-1765.
10. Mittler J, Essunger P, Yuen GJ, Clendeninn N, Markowitz M, and Perelson AS: Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy. Antimicrob Agents Chemother 2001;45:1438-1443.
11. Mueller BU, Zeichner SL, Kuznetsov VA, Heath-Chiozzi M, Pizzo PA, and Dimitrov DS: Individual prognoses of longterm responses to antiretroviral treatment based on virological, immunological and pharmacological parameters measured during the first week under therapy. AIDS 1998;12:F191-F196.
12. van Leth F, Huisamen CB, Badaro R, et al.: Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy. J Acquir Immune Defic Syndr 2005;38:296-300.
13. Bekker V, Scherpbier HJ, Steingrover R, et al.: Viral dynamics after starting first-line HAART in HIV-1-infected children. AIDS 2006;20:517-523.
14. Hirsch M, Brun-Vezinet F, Clotet B, et al.: Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2003;37:113-128.
15. The EuroGuidelines Group for HIV Resistance: Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as a part of treatment management: Recommendations for the European setting. AIDS 2001;15:309-320.
16. Department of Health and Human Services (DHHS): Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, December 1, 2007. Available at http://www.hivatis.org Accessed: December 28th 2007.
17. MacManus S, Yates PJ, Elston RC, White S, Richards N, and Snowden W: GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: Absence of protease resistance at 48 weeks. AIDS 2004;18:651-655.
18. Walmsley S, Bernstein B, King M, et al.: Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346:2039-2046.
19. Conradie F, Sanne I, Venter W, and Eron J: Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient. AIDS 2004;18:1084-1085.
20. Friend J, Parnik N, Liegler T, Martin JN, and Deeks GS: Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS 2004;18:1965-1966.
21. Aleman S, Soderbarg K, Visco-Comandini U, Sitbon G, and Sonnerborg A: Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 2002;16:1039-1044.
22. Napravnik S, Edwards D, Stewart P, Stalzer B, Matterson E, and Eron JJ: HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr 2005;40:34-40.
23. Kristiansen TB, Pedersen AG, Eugen-Olsen J, Katzenstein TL, and Lundgren JD: Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression. Scand J Infect Dis 2005;37:890-901.
24. Kantor R, Shafer RW, Follansbee S, et al.: Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS 2004;18:1503-1511.
25. Resch W, Parkin N, Watkins T, Harris J, and Swanstrom R: Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir. J Virol 2005;79:10638-10649.
26. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006;14:125-130.
27. Ciancio BC, Trotta MP, Lorenzini P, et al.: The effect of number of mutations and of drug-class sparing on virological response to salvage genotype-guided antiretroviral therapy. Antiviral Ther 2003;8:611-616.
28. Tozzi V, Zaccarelli M, Bonfigli S, et al.: Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: Prevalence, risk factors and virological outcome. Antiviral Ther 2006;11:553-560.
29. Acquaro S, D'Arrigo R, Svicher V, et al.: Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother 2006;58:714-722.
30. Murri R, Ammassari A, Trotta MP, et al.: Patient-reported non-adherence to HAART is related to protease inhibitor levels. J Acquir Immune Defic Syndr 2000;24:123-128.
31. Markowitz M and Perelson AS: HIV-1 viral dynamics studies in the setting of clinical trials. A window of opportunity. J Infect Dis 2007;195:1087-1088.